Monday, May 2, 2011

Tradjenta (Linagliptin) Tablets for Type 2 Diabetes

From FDA news release: FDA approves new treatment for Type 2 diabetes. The clinical trial mentioned in this news release seems to be this one: Safety and Efficacy of BI 1356 as Monotherapy or in Combination in Type 2 DM.
According to MedlinePlus, Type 2 Diabetes is a chronic (lifelong) disease marked by high levels of sugar (glucose) in the blood. The chronic (lifelong) part makes it very attractive target for Pharma. There are currently more than 60 clinical trials for Diabetes Mellitus, Type 2 including new clinical trials that use linagliptin, and other dipeptidyl peptidase 4 (DPP4) inhibitors.

Additional information from Wikipedia: